Clinical Trials Browser

Withdrawn × Carcinoma, Transitional Cell × Docetaxel × Clear all

NCT01071928 2015-08-19

Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma

Phase 2 Withdrawn

Carcinoma, Transitional Cell

NCT01907308 2014-04-29

Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma

Phase 2 Withdrawn

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell